Roche/Igen settlement?
This article was originally published in The Gray Sheet
Executive Summary
Igen hires Goldman Sachs as strategic advisor, heightening pressure on Roche as the firms discuss a possible settlement of patent litigation and Igen weighs options to maximize shareholder value - including other development partners for Igen's Origen diagnostics technology. Gaithersburg, Maryland-based Igen was awarded $505 mil. by a Maryland federal court in January after Igen filed suit in 1997, charging Roche with breaching an Origen license agreement (1"The Gray Sheet" Jan. 14, 2002, p. 31.) Roche, which said it would appeal the decision, confirms that settlement talks are ongoing...
You may also be interested in...
Roche To Appeal $505 Mil. Jury Decision Granting Igen Elecsys Rights
Igen International will gain the rights to Roche Diagnostic's Elecsys diagnostic product line under a $505 mil. verdict reached Jan. 10 in Maryland federal court
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.